Monday, June 4, 2007

Amgen to acquire Ilypsa for $420 million cash

(Reuters) - Santa Clara, California-based Ilypsa's lead experimental
drug candidate is ILY101, which is designed to treat
hyperphosphatemia in chronic kidney disease in patients on
hemodialysis.




Read more at Reuters.com Mergers News
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)